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ABSTRACT
Epilepsy is common in people with intellectual and developmental disabilities (IDD). In adulthood, pa-
tients with IDD and epilepsy (IDD-E) have neurologic, psychiatric, medical, and social challenges com-
pounded by fragmented and limited care. With increasing neurologic disability, there is a higher
frequency of epilepsy, especially symptomatic generalized and treatment-resistant epilepsies. The
causes of IDD-E are increasingly recognized to be genetic based on chromosomal microarray analysis
to identify copy number variants, gene panels (epilepsy, autism spectrum disorder, intellectual disabil-
ity), andwhole-exome sequencing. A specific genetic diagnosismay guide care by pointing to comorbid
disorders and best therapy. Therapy to control seizures should be individualized, with drug selection
based on seizure types, epilepsy syndrome, concomitant medications, and comorbid disorders. There
are limited comparative antiepileptic drug data in the IDD-E population. Vagus nerve and responsive
neural stimulation therapies and resective surgery should be considered. Among the many comorbid
disorders that affect patientswith IDD-E, psychiatric and sleep disorders are common but often unrec-
ognized and typically not treated. Transition from holistic and coordinated pediatric to adult care is
often a vulnerable period. Communication among adult health care providers is complex but essential
to ensure best care when these patients are seen in outpatient, emergency room, and inpatient set-
tings. We propose specific recommendations for minimum care standards for people with IDD-E.
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GLOSSARY
AED 5 antiepileptic drug; IDD 5 intellectual and developmental disabilities; IDD-E 5 intellectual and developmental dis-
abilities and epilepsy; NES 5 nonepileptic seizures; QOL 5 quality of life; RNS 5 responsive neurostimulation; SUDEP 5
sudden unexpected death in epilepsy; TRE 5 treatment-resistant epilepsy; VNS 5 vagus nerve stimulator.
Living with intellectual and developmental disabilities (IDD) and epilepsy (IDD-E) holds chal-
lenges for the individual, caregivers, and family. Activities of daily living and quality of life
(QOL) can be affected by comorbid physical, mental, or cognitive disabilities, as well as epilepsy.
Despite progress in care, many problems persist, including a failure to provide medical student
and resident education about IDD-E populations. Current adult epilepsy services are often
unable to adequately address the needs of this population, who face disparities in health care.
Medical science has failed to provide evidence-based data on the care of patients with IDD-E.
Randomized controlled trials are needed.
This article, based on a workshop, highlights areas where a greater understanding of the issues
and an application of current knowledge could improve the quality of care and QOL in the
IDD-E population. We identify areas in which a change in clinical management should be con-
sidered and recommend minimum care standards that have excellent face validity but are not
evidence-based, reflecting a paucity of rigorous research in this population.
FOCUS ON MANAGEMENT CHANGE The following key questions can be asked of the neurology commu-
nity, to which a positive answer would undoubtedly lead to major improvements in care of adult patients with
IDD-E:
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1. Can we improve the education of health care
workers about IDD-E?
2. Can we better define the epidemiology and the
risk factors for comorbid disorders such as autism
spectrum disorder and anxiety disorder?
3. Can we adapt investigative and diagnostic serv-
ices to enhance access of care?
4. How can we help ease the burden of caregivers?
5. Can adult epilepsy providers improve accurate
syndrome diagnosis and complement these with
genetic investigation if needed?
6. Should we apply medication (newer antiepileptic
drugs [AEDs]), dietary, and surgical assessment
and treatment for the same indications and
extent as in epilepsy patients without IDD?
7. How should we measure physical, cognitive, and
behavioral side effects of epilepsy treatment?
8. Are psychiatric classifications and diagnostic cri-
teria valid?
9. Do psychiatric care resources adequately provide
the expertise needed for care?
10. Do patients and caregivers have an emergency
treatment plan and longitudinal plan of care?
11. Is research to assess and treat patients with IDD-E
commensurate with the problem?
NATURE OF THE EPILEPSY Factors such as chro-
nicity, etiology, syndrome, and seizure type differ
between the adult IDD-E and general epilepsy
populations. These factors may be influenced by the
severity of the IDD. The epilepsy usually begins in
childhood. In a UK primary care population of
354,000 adults and children, 374 adults with IDD
were identified; among those who consented, 18%
(58/318) had epilepsy and 92% had childhood-
onset epilepsy.1
The age at onset of the epilepsy may be influenced
by etiology. In Down syndrome, for example, the 2
peaks of epilepsy onset are infancy (often infantile
spasms) and mid-adulthood (often myoclonic seizures
shortly before dementia).2,3 This second peak reflects
the increasing life expectancy, from 5 years in 1955 to
over 55 years at present.
The prevalence of epilepsy increases with the
severity of the IDD. Among 692 patients with
childhood-onset epilepsy followed for 20–30 years,
147 (21%) had IDD-E.4,5 Of these 147 IDD-E cases,
53% had severe/profound IDD compared to 24%
with moderate IDD and 24% with mild IDD.4
Seizure type is also influenced by the severity of
the IDD. Focal epilepsies predominate in those with
mild IDD (69%; 17% with symptomatic generalized
epilepsy), similar to those with normal intelligence,
while symptomatic generalized epilepsies predomi-
nate in those with severe IDD (67%; 29% with focal
epilepsy).5 More than 30% of people with IDD-E
have symptomatic generalized epilepsies that do not
match a defined syndrome.5 Epilepsy in those with
moderate and severe/profound IDD is often more
severe and treatment-resistant than in those with mild
IDD (table 1; p 5 0.004),5 who have similar long-
term epilepsy outcomes to those with normal intelli-
gence (table 1).
Some childhood-onset syndromes continue into
adulthood with different features. Lennox-Gastaut is
less easily defined in adults than children.6 The early
characteristic slow spike-wave discharges on EEG
tend to vanish in adulthood and are replaced with
multifocal spikes. Tonic seizures during sleep often
persist with generalized fast spikes; however, clinical
drops, absence, and myoclonus become less frequent.
Adult seizures may be predominantly focal or gener-
alized tonic-clonic.
Epilepsy histories in adults with IDD are challeng-
ing, especially when the caregiver has limited knowl-
edge of the patient. Important diagnostic details may
be unavailable. For example, a history of status epilep-
ticus in the first year of life with fever or after vaccina-
tion, or exacerbation of seizures with carbamazepine,
would suggest Dravet syndrome.
Successful care of adults with IDD-E depends on
applying recent advances in genetic evaluation, ongo-
ing epilepsy and treatment impact, collecting accurate
data, addressing psychological comorbidity, and opti-
mizing care transition.
GENETIC EVALUATION Identifying the etiology.
IDD often results from genetic causes, including
copy number variants, Mendelian disorders, and
de novo mutations. Karyotyping and genetic
sequencing of IDD-related genes (e.g., trisomy 21
Table 1 Role of IDD in epilepsy types and
remission
Remission, %
Intractable
epilepsy, %
All epilepsies
Mild IDD 49 14
Moderate IDD 32 38
Severe/profound IDD 24 55
Focal epilepsy only
Normal intelligence 68 15
Mild IDD 57 10
Moderate IDD 28 30
Severe/profound IDD 28 44
Abbreviation: IDD5 intellectual and developmental disabilities.
Remission of Epilepsy in Nova Scotia study: severity of the
IDD.5
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and FMR1 repeats in fragile X) are standard
diagnostic tools. Genetic syndromes with copy
number variations (duplications and deletions) can
be identified with chromosomal microarray analysis.
In highly recurrent copy number variants, candidate
genes for both IDD and epilepsy have been
identified in duplicated or deleted regions.
Causative copy number variants occur in 15%–
20% of unexplained IDD or multiple congenital
anomalies (table 2)7 and are commonly found in
patients with autism spectrum disorder and
epilepsy.8,9 Hotspots in chromosomes 15 and 16
for such variants are common in patients with
IDD, autism spectrum disorder, and epilepsy.9
Chromosomal microarray analysis is covered by
most insurances and this first-line test can help
diagnose unexplained IDD-E.
Gene panels can identify causes of IDD, autism
spectrum disorder, and epilepsy due to Mendelian
disorders or de novo mutations. These tests are
expensive and may not be covered by some insurers.
When a suspected disorder may impact therapy
(e.g., tuberous sclerosis, SCN1Amutation), a stronger
argument for testing can be made. Whole-exome
sequencing is best arranged by a clinician with genet-
ics expertise, as variants of uncertain significance are
common. When variants are found, testing of the
biological parents can help determine whether the
mutation is inherited or de novo.
Does genetic information affect clinical care? Many
adults with IDD-E have genetic disorders for which
identification can (1) have an immediate impact on
diagnosis, treatment, and prognosis, (2) identify
preventable or treatable comorbid disorders, (3)
inform the family about genetic counseling, (4)
provide an explanation that relieves guilt, and (5)
provide patient and caregiver support through
syndrome-specific advocacy groups (figure 1). Soon,
medications may treat nonsense (premature stop
codon) haploinsufficiency mutations (e.g., SCN1A,
CDKL5).
METABOLIC ASSESSMENT Nearly 90 treatable
metabolic disorders can present with IDD10; many
cause epilepsy. Screening for these disorders can be
done in 2 phases. Initial assessment with urine and
blood tests can identify up to 60% of all treatable
inborn errors of metabolism. Secondary investiga-
tions are determined on individual clinical features
and often obtained after consultation with a geneticist
or metabolic specialist. An app to assist with this
investigation provides a diagnostic algorithm (www.
treatable.id.org).
TREATMENT IMPACT Many people with IDD-E
have treatment-resistant epilepsy (TRE) with
generalized or multifocal seizures that are not surgically
amenable. Video-EEG, when feasible to perform, can
confirm the seizure type and epilepsy syndrome and
assess nonepileptic seizures (NES), medication toxicity,
and other diagnostic challenges. The interplay of
seizure reduction, EEG improvement, and side effects
make it difficult to define the AED effects in this
population. Impairments in cognition, behavior, and
coordination due to AEDs may be wrongly
attributed to the underlying IDD, termed diagnostic
overshadowing.
Thirteen randomized controlled studies with 899
patients with IDD-E studied carbamazepine, cloba-
zam, felbamate, gabapentin, lamotrigine, rufinamide,
and topiramate.11,12 No features distinguished AEDs
with respect to efficacy or side effects. The Cochrane
Table 2 Examples of recurrent copy number variants associated with ID,
epilepsy, and other neurodevelopmental phenotypes50,51
Copy number variant
Deletion or
duplication Associated phenotypes
1p36 Deletion/duplication ID, ASD (Del), EPI (Del)
1q21.1 Deletion/duplication ID, ASD, SCHZ, EPI
2p16.3 Deletion ID, SCHZ, EPI
2q13 Deletion/duplication ID, ASD, EPI (Del)
2q37 Deletion ID, ASD, EPI
3q29 Deletion/duplication ID (Del), SCHZ, EPI (Del)
4p16.3 (Wolf-Hirschhorn syndrome) Deletion ID, EPI
4q21.21-q21.22 Deletion ID, ASD, EPI
5q35.2-q35.3 (Sotos syndrome) Deletion ID, EPI
7q11.22-q11.23 Deletion/duplication ID, EPI, ASD (Dup)
9q34.3 (9q subtelomeric syndrome) Deletion ID, ASD, EPI
15q11.2 Deletion ID, ASD, SCHZ, EPI
15q11-q13 (Prader-Willi/Angelman
syndrome)
Duplication/deletion ID, ASD (Dup), SCHZ (Dup),
EPI
15q13.3 Deletion/duplication ID, ASD, SCHZ (Del), EPI
16p11.2 Deletion/duplication ID, ASD, SCHZ (Dup), EPI
16p12.1 Deletion ID, ASD, EPI
16p13.11 Deletion/duplication ID, SCHZ (Dup), EPI (Del)
17p12-p11.2 (Potocki-Lupski/Smith
Magenis syndromes)
Deletion/duplication ID, ASD (Dup), EPI
17p13.3-13.2 (Miller-Dieker syndrome) Deletion ID, ASD, EPI
17q12 Deletion/duplication ID, ASD, SCHZ (Del), EPI
17q21.3 Deletion ID, ASD, EPI
22q11 (Velocardiofacial/DiGeorge
syndrome)
Deletion/duplication ID, ASD (Dup), SCHZ (Del), EPI
22q11.2 Deletion ID, ASD, EPI
22q13 (Phelan-McDermid syndrome) Deletion ID, ASD, EPI
Xp22.1 Deletion ID, ASD, EPI
Abbreviations: ASD5 autism spectrum disorders; EPI5 epilepsy; ID5 intellectual disability;
SCHZ 5 schizophrenia.
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reviewers advised making epilepsy care decisions
based on etiology and standard practice, not the
IDD.11
Less rigorous studies have yielded similar, often
mixed results. Lamotrigine may improve aggression,
mood, and alertness when compared to other
AEDs.13 However, individual responses vary consid-
erably, and all AEDs can cause behavioral toxicity in
patients with IDD-E, including generally well-
tolerated ones such as lamotrigine14 and gabapentin.15
Treatment algorithms and recommendations
based on literature review and clinical experience sug-
gest several maxims.16,17 AEDs with potential benefits
on comorbid mood disorders in IDD-E, based largely
on anecdotal observations, include valproate, lamotri-
gine, and oxcarbazepine.13–15 Treatment should focus
on the underlying epilepsy syndrome11,16,17 and take
into account prior attempts to withdraw AEDs (e.g.,
did they precipitate status?).
The use of dietary therapies in adults with IDD-E
is far less common than in childhood, possibly due to
adherence problems. The modified Atkins diet has
expanded dietary therapies to adults.18 This high
fat, very low carbohydrate diet is initiated as an out-
patient, with carbohydrate restriction but no limits on
protein, fluid, or calorie intake. Adult epilepsy dietary
programs can transition adolescents on dietary ther-
apy, providing a medical home for these adults who
require this complicated treatment. Adults with
IDD-E can do well on the modified Atkins diet, sim-
ilar to other adults without disability (E.H. Kossoff,
MD, unpublished data, 2015).
VAGUS NERVE STIMULATION Vagus nerve stimu-
lator (VNS) may help patients with IDD-E since a
partial reduction in seizure frequency or intensity or
AEDs can improve QOL. Uncontrolled trials
suggest VNS is effective and well-tolerated by
diverse IDD cohorts, including Lennox-Gastaut
syndrome and autism spectrum disorder.19
Caregivers may fear that lack of an aura or inability
to use the magnet themselves may render the device
ineffective. However, the magnet can be used by care-
takers and its efficacy remains unproven. Nonverbal
patients can usually express discomfort through vocal
or facial expressions which can be linked to the VNS
on cycle. Impaired voice quality is not an issue for
nonverbal patients.
RESPONSIVE NEUROSTIMULATION The respon-
sive neurostimulation (RNS) device is an adjunctive
therapy for TRE in individuals 18 years of age or old-
er with focal seizures who have 1 or 2 epileptogenic
foci. During the pivotal blinded study, there was a
38% seizure reduction in RNS vs 17% in the sham
treatment. In the open-label phase, there was a
44% reduction after 1 year and 53% after 2 years.20
Among 8 subjects who had an IQ,70, there was no
Figure 1 Hierarchical impact of genetic diagnoses on treatment of epilepsy and comorbid disorders
Hierarchical impact that genetic diagnoses can have on treatment of epilepsy and comorbid disorders in patients with intel-
lectual and developmental disabilities and epilepsy. For almost all cases, genetic diagnosis provides answers and connects
families to a community. In a smaller number of cases, genetic diagnosis can improve recognition of comorbid disorders and
therapeutic choices.
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difference in responder rate for seizure reduction
compared to the group with higher IQ (M. Morrell,
MD, personal communication, 2015).
EPILEPSY SURGERY Historically, patients with
moderate to severe cognitive impairment were con-
sidered poor candidates for epilepsy surgery due to
presumed multilobar dysfunction.16 However, among
children and adults with TRE and a localized epilep-
tic focus, IQ does not predict surgical outcome.21
In syndromes such as tuberous sclerosis with IDD
and multiple structural and potentially epileptogenic
lesions, removal of a dominant focus or even bilateral
foci can markedly reduce or completely control seiz-
ures.22 Functional hemispherotomy can be curative.
Callosotomy and multiple subpial resections may
improve seizure control.
MORTALITY AND COMORBIDITIES Common causes
of mortality in IDD-E include cardiovascular
disease, respiratory infections, cancer, epilepsy, and
accidents. In a UK survey of IDD, the median age
of death was 13 years younger in male and 20 years
younger in female patients compared to the general
population23; 37% of the deaths were avoidable.
Factors contributing to premature mortality include
problems in advanced care planning, failure to
address mental health issues, living in inappropriate
accommodation, adjusting care as needs changed, and
caregivers not feeling listened to.
Patients with IDD-E have comorbid disorders
that impact epilepsy and its management. Collabo-
rating with medical doctors and specialists experi-
enced with the IDD population can improve care.
Commonly overlooked morbidities in IDD-E
include gastrointestinal, gynecologic, urologic,
psychiatric, dental, sensory (e.g., visual, auditory),
polypharmacy, and sleep disorders, as well as neglect
and abuse, falls, and injuries.
Sleep disorders occur in 30%–60% of adults
with IDD and are often undiagnosed.24 These
include insomnia, apnea, circadian rhythm, para-
somnias, and daytime hypersomnia disorders.
Severity of IDD, cerebral palsy, and epilepsy are
associated with an increased risk of sleep disor-
ders.25 Contributing factors to sleep disorders in
IDD-E include muscle spasms, musculoskeletal
pain, inability to change body position at night,
medications, visual impairment, glossopteris, or
abnormal upper airway leading to obstructive sleep
apnea, reflux, and aspiration pneumonias, and psy-
chological/behavioral factors.25
Psychiatric disorders result from the underlying
etiology of IDD, epilepsy (peri-ictal dysfunction,
forced normalization), genetics, AEDs and other
medications, and living circumstances (figure 2).26
Psychiatric disorders often impair QOL more than
seizures. Patients with IDD-E are 7-fold more likely
to develop psychiatric disorders than those with IDD
only, supporting the etiologic role of epilepsy.26 Envi-
ronment should be considered. For example, antago-
nistic relations with housemates can fuel depression
or aggression that is often best managed without med-
ication.27 Psychiatric and psychological evaluations
are often essential. Behavioral therapies, psychotropic
medications, and environmental changes should all
be considered. Psychotropic medications are often
underutilized in IDD-E and other epilepsy patients
due to unfounded fears that these medications com-
monly provoke seizures. Psychotropic drugs are safe
and effective in epilepsy patients.28 For patients on
chronic psychotropic medication, re-evaluation to
Figure 2 Factors contributing to the genesis and persistence of psychiatric disorders in patients with
intellectual and developmental disabilities and epilepsy
ADHD 5 attention-deficit/hyperactivity disorder.
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assess the necessity of ongoing, often polytherapy
should be done at least once a year.
AEDs are a common and remediable cause of psy-
chiatric disturbances (e.g., hyperactivity, irritability,
and aggressive behavior) in patients with IDD-E.
While any AED at high doses can change behavior,
several AEDs are prone to cause psychiatric symp-
toms in vulnerable patients (e.g., previous or family
psychiatric history); these AEDs include GABAergic
drugs (barbiturates,29 benzodiazepines,30 vigabatrin,
tiagabine,31 and levetiracetam).16,32 Much of these
data are anecdotal.
In patients with IDD-E, high seizure frequency,
tonic-clonic seizures, and AED polytherapy are asso-
ciated with behavioral disorders.33 The most fre-
quent expressions of psychopathology in people
with IDD-E are aggressive, impulsive, and opposi-
tional behavior, although mood, anxiety, and psy-
chotic disorders are also common. We lack
evidence-based treatment algorithms in the IDD
or IDD-E populations34 to treat agitation, self-
injurious behaviors, and other forms of aggression.
Whenever possible, physical and pharmacologic
restraint should be avoided or minimized. Behav-
ioral interventions (e.g., antecedent interventions,
differential reinforcement, extinction, functional
communication, response interruption)35 and regu-
lar exercise may be very helpful.27
Misdiagnosis is common. Stereotyped behaviors
can be confused as aggressive behavior or a sign of a
seizure. Stereotypies may be the expression of self-
stimulation or a movement disorder. NES are com-
mon in people with IDD-E. In populations of
patients with NES, 30%–40% have IDD and con-
comitant epilepsy.36
EPILEPSY IMPACT: MORBIDITY AND MORTALITY
Epilepsy complications may result from seizures, ther-
apies to control seizures, or the underlying etiology.
Patients with IDD and comorbid epilepsy have 2–3
times the utilization of inpatient, outpatient, and
accident/emergency visits than those with IDD
alone.37 More data on patients with IDD-E are
needed, and most of what follows refers to
individuals with epilepsy, not IDD-E.
Seizure-related injury. A prospective, multicenter, case-
control study found an increased injury rate in
persons with epilepsy vs controls (27% vs 17%,
p , 0.0001).38 The risk in multi-handicapped adults
with epilepsy in nursing homes was greater: one-third
sustained a seizure-related injury over 13 months.39
Table 3 Minimum care standards for adults with intellectual and developmental disabilities and epilepsy
Health care providers should be educated about the medical, cognitive, and behavioral comorbidities
Health care providers should be instructed to be patient-centered in communication: for example, to make eye contact, to speak to the person even if he or she is
nonverbal, and to show the same respect as for any other patient
In every patient, the diagnosis should be carefully assessed, no matter what the age of the patient, with regards to underlying cause, epilepsy syndrome, and comorbid
disorders
Consider genetic disorders that could impact therapy (e.g., Dravet syndrome)
Consider atypical presentations of epilepsy syndromes (e.g., Lennox-Gastaut syndrome without slow spike and wave or daytime tonic seizures)
Autism spectrum and other psychiatric disorders are often comorbid; their identification may improve care access and help tailor therapy
As children reach adolescence, they and their caregivers should be educated about their care and transition to adult care should be planned in advance; adult epilepsy
specialist care is usually required
Families should be educated on the nature of adult epilepsy care and an adult care provider identified
A brief personal and medical summary should be prepared and updated annually, and be available for all individuals involved in the care of the patient with IDD-E; this
should include past and current diagnoses, medications and beneficial/adverse effects, allergies, and personal preferences (e.g., ways to calm the patient in a stressful
setting)
Assess the AED regimen efficacy and safety during every clinical visit; consider misattribution of AED side effects to the IDD (diagnostic overshadowing)
For patients with treatment-resistant epilepsy, consider dietary or surgical therapies
Consider preventive strategies to reduce chances of injury or premature death, including risk from injury, drowning, and SUDEP; assess living accommodations and
consider social work involvement if needed
Consider the needs of family members and the potential burden they are experiencing and refer for support as needed
An individualized seizure emergency management plan should be part of the medical summary
Integration of care among all health providers, with one provider identified as the coordinator; care should always include careful listening to the patient with IDD-E and
inclusion of his or her input with respect to care decisions
Mental health should be reviewed at every visit; referral to mental health support should be considered when concerns arise
Ongoing awareness is needed to assess for changes in neurologic and medical health; be aware of red flags such as weight loss, behavior change, and loss of appetite for
unrecognized physical comorbidity
Abbreviations: AED5 antiepileptic drug; IDD 5 intellectual and developmental disabilities; IDD-E 5 intellectual and developmental disabilities and epilepsy;
SUDEP 5 sudden unexpected death in epilepsy.
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Seizures may result in injury due to falls or altered
awareness impairing response to dangerous situations.
Risk factors for falls in people with IDD may include
older age, impaired mobility, epilepsy, and behavioral
problems.40 Accidental injury may also result from
AED toxicity, osteoporosis exacerbated by
medication and immobility due to IDD, attention-
deficit disorder, and impaired motor function. Soft
tissue injuries are the most common injury sustained
with seizures. Most are mild, with only 5% requiring
medical attention.38 Fractures, most significantly hip
and femur, are increased 2- to 6-fold in an epilepsy
cohort vs the general population.41
Drowning. In the preceding year, 14% of adults with
active epilepsy sustained a seizure while bathing or
swimming.42 Drowning deaths most often occurred
with unsupervised baths. We recommend (1) taking
showers rather than baths, (2) avoiding pop-up/down
drains in the shower, (3) careful supervision around
water, and (4) life jackets during water activities on or
around lakes and open water.
Burns. Seizure-related burns account for 1.6%–
3.7% of burn unit admissions.41 Risk factors for
burns include higher number of lifetime seizures,
absence of neurologic impairment, and seizures that
impair consciousness with or without secondary
generalization.41
Head injury. Concussion rate is elevated in patients
with epilepsy compared to controls.38 The risk is
greater in adults with chronic epilepsy, especially if
seizures cause falls. While helmets are often recom-
mended for patients with recurrent seizure-induced
falls, their efficacy remains unproven.
Strategies to minimize risk of accidental injury. Injury
risk is greatest in persons with generalized seizures
without auras and high seizure frequency. Counsel-
ing on risks of submersion injury and water safety is
essential. Vitamin D supplementation and encour-
aging outdoor activities and regular physical exer-
cise promotes bone health. For those with
TRE, minimizing use and exposure to heated appli-
ances and limiting hot water settings may reduce
risk of burns. Environmental measures can reduce
risk of falls.
SEIZURE-RELATED DEATH Status epilepticus. Mor-
tality due to status epilepticus is higher in epilepsy
syndromes characterized by recurrent status epilepti-
cus. For example, one-third of deaths in Dravet
syndrome were attributed to status epilepticus43
compared to 6%–16% for epilepsy overall.44
Sudden unexpected death in epilepsy. Sudden unex-
pected death in epilepsy (SUDEP) is the most com-
mon cause of death among people with TRE. The
risk of SUDEP increases with the frequency of gener-
alized tonic-clonic seizures. Symptomatic epilepsy
and IDD are risk factors for SUDEP.45–47
Supervision, especially at night, may reduce SUDEP
in children and adults with IDD-E.48 Since most
SUDEPs occur in sleep and patients are in the
prone position, seizure monitors that can alarm
caregivers may help to reduce SUDEP risk, but this
remains unproven.48
CRITICAL ISSUES IN CARE DELIVERY Transition
from pediatric to adult care. Medical transition is a
dynamic longitudinal process that is disruptive and
stressful for patients and families. Many child neurol-
ogy providers do not utilize a transition process.
IDD-E increases the need for parental involvement
in care. Plans must be made for adults with IDD-E
who live with elderly parents. Transition clinics,
usually in the adult medical setting, promote self-
determination and positive transition. Many adult
neurologists are uncomfortable with IDD patients.
Gaps remain in access to expertise in IDD-E for
some patients living in rural regions or with lower
socioeconomic resources. Formal training about
IDD care should become a part of all neurology
and epilepsy training programs.
Data and communication. Support and care for adults
with IDD-E are often provided by aging parents,
rotating group home staff, and institutional care
providers. Accurate clinical information is often
difficult to obtain, a challenge exacerbated by
language and cognitive impairments. Clinicians
should always make eye contact with patients, ask
questions even if patients are nonverbal since
comprehension usually exceeds expressive skills, and
use person-first language (“person with disabilities,”
not “disabled person”) as signs of respect and caring.
Caregiver relations. The burden of caregivers is enor-
mous and is rarely appreciated by health care workers.
Stress can result from financial concerns, witnessing
and providing care for seizures and status epilepticus,
behavioral and mood disorders, provision of overall
care (e.g., bathing), managing incontinence and spas-
ticity, and scores of other challenges. Aging parents
benefit from social service referrals and support
groups.
Emergency and hospital care. The high rate of hospital-
ization among the IDD-E population could be
reduced through preventive measures and regular
ambulatory care. Emergency care is often for
seizures, seizure clusters and status epilepticus,
seizure-related injuries, medication toxicities, or
behavioral crises. Adults living with family or in
long-term care facilities may be managed without
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hospitalization as families and health care workers
become expert with acute seizure management.
Residents of community-based group homes often
use the emergency ward since staff have high
turnover and limited experience.
Barriers to medical care in patients with IDD
include limited communication, agitation in unfamil-
iar and overstimulating hospital environments, and
physical and neurologic impairments confounding
assessment of physical or cognitive changes. Extrinsic
barriers include limited or inaccurate medical history
and test data, as well as access to specialized centers.
Written or electronic summaries of the patient’s his-
tory are invaluable.
Management during hospitalizations. In the emergency
ward or hospital, patients with IDD-E should be
managed with as few restrictions and as much
familiarity as possible (e.g., known companion,
familiar foods). Calmly explaining procedures step-
by-step can help even nonverbal patients. Agitation
or poor cooperation may lead to pulling off EEG
electrodes or IV access. Patients trying to get out of
bed are at risk of falling. Established protocols help
to manage these problems as well as aggression.
Intermittent ambulation can help preserve
strength and reduce risk of deep vein thrombosis.
Recreation therapy is helpful. The family and other
caretakers should be regularly informed during hospi-
talization with clear discharge instructions including
medication changes and potential side effects.
Emergency seizure management. Every patient should
have a written seizure action plan including emer-
gency contact information, preferred hospital, medi-
cation doses, and allergies. Caregivers should know
basic seizure first aid and how to treat prolonged or
clustered seizures (rescue medication dose and
repeated use, and when to call for emergency medical
services). Physicians need to consider causes of wors-
ening seizure control (e.g., nonadherence, hydroceph-
alus, low AED levels).49
Minimum care standards for adults with IDD-E. Our
recommendations to improve the health care of adults
with IDD-E are summarized in table 3.
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